Suppr超能文献

他汀类药物治疗史与体外膜肺氧合治疗后的死亡率:一项回顾性、基于人群的队列研究。

Prior Statin Therapy and Mortality After Extracorporeal Membrane Oxygenation Therapy: A Retrospective, Population-Based, Cohort Study.

机构信息

Department of Cardiology, Cardiovascular Center, Seoul National University Bundang Hospital, Seongnam, South Korea.

Department of Anesthesiology and Pain Medicine, Seoul National University Bundang Hospital, Seongnam, South Korea.

出版信息

J Cardiothorac Vasc Anesth. 2021 Dec;35(12):3612-3619. doi: 10.1053/j.jvca.2021.02.019. Epub 2021 Feb 12.

Abstract

OBJECTIVE

To investigate whether prior statin therapy is associated with an improvement in mortality among patients who undergo extracorporeal membrane oxygenation (ECMO) therapy.

DESIGN

Retrospective, population-based, cohort study.

SETTING

Health records were obtained from the National Health Insurance Service database in South Korea.

PATIENTS

All adult patients (≥18 y) who underwent ECMO therapy in the intensive care unit between 2005 and 2018 were enrolled.

EXPOSURES

Statin users were defined as patients who were prescribed continuous oral statins ≥90 days before ECMO.

MEASUREMENTS AND MAIN RESULTS

The primary endpoint of this study was 90-day mortality. A total of 21,129 adult patients from 128 hospitals were included (4,737 [22.4%] statin users and 16,392 [77.6%] nonusers). After propensity score matching, 9,474 ECMO patients (4,737 in each group) were included in the final analysis. In the propensity-score-matched cohort, statin users exhibited lower 90-day mortality than did nonusers (58.6% [2,774/4,737] in statin users v 65.6% [3,106/4,737] in nonusers). In addition, on Cox regression, 90-day mortality in statin users was 14% less than that in nonusers (hazard ratio 0.86, 95% confidence interval 0.81-0.90; p < 0.001).

CONCLUSION

Among patients who underwent ECMO in South Korea, prior statin therapy was found to be associated with lower 90-day mortality rates after ECMO therapy. However, because this study had a retrospective design, future prospective trials are needed to confirm the findings.

摘要

目的

研究体外膜肺氧合(ECMO)治疗患者中,预先使用他汀类药物治疗是否与死亡率的改善相关。

设计

回顾性、基于人群的队列研究。

设置

研究数据来自韩国国家健康保险服务数据库中的健康记录。

患者

纳入 2005 年至 2018 年间在重症监护病房接受 ECMO 治疗的所有成年患者(≥18 岁)。

暴露

他汀类药物使用者定义为在 ECMO 前≥90 天连续口服他汀类药物的患者。

测量和主要结果

本研究的主要终点为 90 天死亡率。共纳入来自 128 家医院的 21129 名成年患者(4737 名[22.4%]他汀类药物使用者和 16392 名[77.6%]非使用者)。经倾向评分匹配后,最终分析纳入 9474 名 ECMO 患者(每组 4737 名)。在倾向评分匹配队列中,他汀类药物使用者的 90 天死亡率低于非使用者(他汀类药物使用者为 58.6%[2774/4737],非使用者为 65.6%[106/4737])。此外,在 Cox 回归中,他汀类药物使用者的 90 天死亡率比非使用者低 14%(风险比 0.86,95%置信区间 0.81-0.90;p<0.001)。

结论

在韩国接受 ECMO 的患者中,预先使用他汀类药物治疗与 ECMO 治疗后较低的 90 天死亡率相关。然而,由于本研究为回顾性设计,需要进一步的前瞻性试验来证实这些发现。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验